New method for monitoring lung cancer after surgery
Official title: Development and Validation of Non-Invasive Monitoring Techniques for Postoperative Recurrence and Novel Adjuvant Therapeutic Strategies in Lung Cancer
Run by Peking University People's Hospital · NCT06930807 · Data updated 2026-11-12
This study is testing a new way to monitor lung cancer after surgery using blood tests to see if it helps patients stay cancer-free longer compared to standard methods.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Peking University People's Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | March 25, 2025 |
| Main results expected | July 31, 2027 |
| Study ends | July 31, 2028 |
| Registry record updated | April 16, 2025 |
| Trial ID | NCT06930807 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults with stage IA-IIIA non-small cell lung cancer who are planning to undergo curative surgery or neoadjuvant therapy.
✕Probably not a fit
Patients with advanced stage IIIB-IV non-small cell lung cancer or those under 18 years old may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to develop innovative techniques for monitoring minimal residual disease (MRD) in patients with early-stage non-small cell lung cancer after surgery. It will evaluate the effectiveness of adaptive treatment guided by ctDNA-MRD compared to traditional management methods. The research will also explore how different patient characteristics affect the outcomes of MRD-guided strategies. By utilizing liquid biopsy technology, the study seeks to enhance the sensitivity of detecting postoperative recurrence and improve patient survival rates.
Why it matters
Potential benefit: If successful, this approach could lead to more effective monitoring and treatment strategies for lung cancer patients, potentially improving survival rates.
How similar studies have gone: Other studies have shown promise in using liquid biopsy techniques for cancer monitoring, indicating potential success for this novel approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Non-small cell lung cancer with stage IA-IIIA (8th edition TNM classification) planning to undergo curative surgery or to undergo neoadjuvant therapy * Solid nodules \>1 cm or ground-glass nodules \>1.5 cm on imaging * No history of malignancies other than non-small cell lung cancer in the past 5 years * Specimens are well preserved and imaging documents are accessible. Exclusion Criteria: * Age\<18 years old * Non-small cell lung cancer with pathologic stage IIIB-IV (8th edition TNM classification) * Pathology results confirmed not to be non-small cell lung cancer * History of malignancies other than non-small cell lung cancer in the past 5 years
Where it's running
-
Peking University People's Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Principal investigator: Yintao Li, MD — Shandong Cancer Hospital and Institute
- Study coordinator: Kezhong Chen, MD
- Email: mdkzchen@163.com
- Phone: +86-010-88325983
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Patient-specific MRD liquid biopsy for resected NSCLC
This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.
-
Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases
This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.
-
ctDNA blood test to spot buried cancer after surgery or treatment in colorectal cancer
A blood test that looks for specific KRAS mutations in circulating tumor DNA to see if colorectal cancer has left residual disease or is likely to relapse.
-
MRD-guided postoperative monitoring and adaptive treatment for resectable NSCLC
This study tests a personalized follow-up and treatment plan using ctDNA MRD testing and pathology to guide adjuvant therapy after surgery for stage IB-IIIA NSCLC treated with neoadjuvant immunotherapy.
-
Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies
This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.